Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685–98.
Josso N. WOMEN IN REPRODUCTIVE SCIENCE: Anti-Müllerian hormone: a look back and ahead. Reproduction. 2019;158:F81–9.
Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol. 2003;211:21–31.
Kuiri-Hänninen T, Kallio S, Seuri R, Tyrväinen E, Liakka A, Tapanainen J. Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab. 2011;96:3432–9.
Josso N, di Clemente N, Gouédard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol. 2001;179(1–2):25–32.
Mullen RD, Wang Y, Liu B, Moore EL, Behringer RR. Osterix functions downstream of anti-Müllerian hormone signaling to regulate Müllerian duct regression. Proc Natl Acad Sci U S A. 2018;115:8382–7.
Shin SY, Lee JR, Noh GW, Kim HJ, Kang WJ, Kim SH, Chung JK. Analysis of serum levels of anti-Müllerian hormone, Inhibin B, insulin-like growth factor-I, insulin-like growth factor binding Protein-3, and follicle-stimulating hormone with respect to age and menopausal status. J Korean Med Sci. 2008;23:104–10.
Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas. 1988;10(1):35–43.
Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1–9.
Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057–63.
Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum anti-Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90:395–400.
Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009;92:1586–93.
Lee JE, Yoon SH, Kim HO, Min EG. Correlation between the serum luteinizing hormone to follicle stimulating hormone ratio and the anti-Müllerian hormone levels in normo-ovulatory women. J Korean Med Sci. 2015;30:296–300.
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–9.
Yetim A, Yetim Ç, Baş F, Erol OB, Çığ G, Uçar A, et al. Anti-Müllerian hormone and inhibin-a, but not inhibin-B or insulin-like peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results. J Clin Res Pediatr Endocrinol. 2016;8:288–97.
Depmann M, Eijkemans MJ, Broer SL, Scheffer GJ, van Rooij IA, Laven JS, et al. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. Hum Reprod. 2016;31:1579–87.
Hagen CP, Aksglaede L, Sørensen K, Mouritsen A, Andersson AM, Petersen JH, Main KM, Juul A. Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012;27:861–6.
Racine C, Rey R, Forest MG, Louis F, Ferré A, Huhtaniemi I, Josso N, di Clemente N. Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci U S A. 1998;95:594–9.
van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83:979–87.
Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril. 2014;101:199–207.
Henderson KD, Bernstein L, Henderson B, Kolonel L, Pike MC. Predictors of the timing of natural menopause in the multiethnic cohort study. Am J Epidemiol. 2008;167:1287–94.
Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril. 2009;92:1674–8.
Khalife D, Nassar A, Khalil A, Awwad J, Abu Musa A, Hannoun A, El Taha L, Khalifeh F, Abiad M, Ghazeeri G. Cumulative live-birth rates by maternal age after one or multiple in vitro fertilization cycles: an institutional experience. Int J Fertil Steril. 2020;14:34–40.
Lebkowska A, Adamska A, Karczewska-Kupczewska M, Nikołajuk A, Otziomek E, Milewski M, et al. Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus. Metabolism. 2016;65:804–11.
Barad DH, Weghofer A, Gleicher N. Comparing anti-Mullerian hormone (AMH) and follicle- stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009;91:1553–5.
Jamil Z, Fatima SS, Cheema Z, Baig S, Choudhary RA. Assessment of ovarian reserve: anti-Mullerian hormone versus follicle stimulating hormone. J Res Med Sci. 2016;21:100.
La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG. 2012;119:1171–9.
Malini NA, Roy GK. Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) – clinical based case control study. Gen Comp Endocrinol. 2018;260:51–7.
Whitcomb BW, Bodach SD, Mumford SL, Perkins NJ, Trevisan M, Wactawski-Wende J, et al. Ovarian function and cigarette smoking. Paediatr Perinat Epidemiol. 2010;24:433–40.
Kofinas JD, Elias RT. Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation. Womens Health. 2014;10:505–9.
Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med. 2014;41:86–91.
Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny. 2017;2:47–50.
Magri F, Schena L, Capelli V, Gaiti M, Zerbini F, Brambilla E, et al. Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. Reprod Biol Endocrinol. 2015;13:106.
Drakopoulos P, van de Vijver A, Schutyser V, Milatovic S, Anckaert E, Schiettecatte J, et al. The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study. Hum Reprod. 2017;32:208–14.